The popularity of Sildenafil initially sparked a period of growth for pharma, however recent shifts present a murky outlook for investors. Off-patent alternatives are eroding earnings, and persistent legal battles add https://nikolascjpy732968.rimmablog.com/39931424/sildenafil-and-pharma-a-volatile-investment